Luffa comp.-Heel®

Nasal Spray

Luffa compositum Heel®

Tablets Composition:

Luffa comp.-Heel Nasal Spray: 100 g cont. Luffa operculata D4, Luffa operculata D12, Luffa operculata D30, Thryallis glauca D4, Thryallis glauca D12, Thryallis glauca D30 10 g each; Histaminum D12, Histaminum D30, Histaminum D200, Sulfur D12, Sulfur D30, Sulfur D200 5 g each. Benzalkonium chloride 0.01% as preservative.

Luffa compositum Heel Tablets: 1 tablet contains: Aralia racemosa D1, Arsenum jodatum D8, Lobelia inflata D6, Luffa operculata D12

25 mg each.

Indications:

Hay fever.

Contraindications:

Nasal-Spray: Hypersensitivity to benzalkonium chloride.

Tablets: The preparation includes an iodine-containing ingredient. In cases of thyroid disorder with reduced iodine tolerance use only on the advice of a physician.

Side effects:

None known.

Interactions with other medication:

None known.

Dosage:

Nasal Spray: In general, spray 1-2 shots into each nostril 3-5 times daily; for children under 6 years, 1 shot 3-4 times daily.

Tablets: In general, 1 tablet to be dissolved under the tongue 3 times daily. In acute disorders, 1 tablet every 15 minutes, over a period lasting up to 2 hours.

Package sizes:

Nasal Spray: Atomiser without propellant, 20 ml. Tablets: Packs containing 50 and 250 tablets.

Pharmacological and clinical notes:

Luffa operculata (loofah sponge) Hay fever.

Thyrallis glauca/Galphimia glauca Allergies of skin and mucous membranes. Histaminum (histamine)

Allergic affections of the skin and mucous membranes. Sulfur (sulphur)

Acute and chronic inflammations of the respiratory organs. Aralia racemosa (North American spikenard)

Allergic affections of the respiratory organs such as hay fever and asthma. Arsenum jodatum (arsenic triiodide)

Bronchitis.

Lobelia inflata (Indian tobacco)

Disorders of the respiratory centre with fall in blood pressure; hay fever; bronchial asthma.

Treatment of a symptom complex under local and systemic aspects is a therapeutic principle with a long tradition of effective results. The constituents of both forms of administration – Luffa comp.-Heel Nasal Spray and Luffa compositum Heel tablets – have accordingly been co-ordinated in such a manner that they effectively complement each other in their therapeutic action.

The constituent common to both forms of administration – Luffa operculata (loofah sponge) – is administered for treatment of the common cold and hay fever.

Additional constituents of Luffa comp.-Heel Nasal Spray are Thyrallis (Galphimia) glauca and histamine: two agents whose therapeutic effectiveness is well known, especially for affections of the skin and mucous membranes. Their therapeutic action  is enhanced by sulphur as stimulation (reversal) remedy for chronic and inflammatory diseases, nervous disorders, and general weakness and debilitation (psychosomatic components).

In addition to Luffa operculata, Luffa compositum Heel tablets also contain the constituents Aralia racemosa (North American spikenard) and Lobelia inflata (Indian tobacco), indicated for common colds and allergic affections of the respiratory organs such as hay fever and asthma. The tablets also contain arsenic triiodide, indicated for common colds, bronchitis, and glandular swelling.

The individual constituents of each of the two forms of administration have been systematically selected and combined, according to their orientation of therapeutic action, to take into effective account a broad field of therapeutic application.

The nasal spray locally acts on the nasal mucosa; the tablets, on the other hand, have systemic effect on the entire organism. The combination of both forms of  administration consequently offers comprehensive relief of symptoms, with enhancement at the same time of prospects for patient compliance.

The following therapy plans are recommended for patients beginning treatment:

For patients with annually recurring symptoms:

Treatment starting 1-2 months before the expected beginning of symptom outbreak, with Luffa compositum Heel tablets, 1 tablet 3 times a day. Upon beginning of the critical hay fever period, additional administration of Luffa comp.-Heel Nasal Spray: 2 spray squirts into each nostril, 3-5 times a day.

For patients with a less pronounced symptom complex (i.e., on the basis of experience gained during the previous year), application of the nasal spray alone will suffice as trial dosage.

In any case, patients should start treatment as early as possible before the initial occurrence of symptoms.

Treatment should extend throughout the entire critical hay fever period and should continue up to 3 weeks afterward. Follow-up therapy during the final weeks can take the form of reduced dosage: 1 tablet before meals, 3 times a day.